The efficiency of dyslipidemia control in real clinical practice and the possibilities of its correction in patients with coronary heart disease and diabetes mellitus in the long -term use of simvastatin

Objective: To show the efficiency of dyslipidemia control in patients with coronary heart disease (CHD) and diabetes mellitus (DM) in real outpatient clinical practice and the possibilities of its correction in the long-term use of simvastatin (simvastatin forte 40 mg) in one of the
Nizhny Novgorod polyclinics.

Subjects and methods. The efficiency of lipid profile control was analyzed in a sample from the entire dispensary group of patients with DM (n = 713). Patients at highest cardiovascular risk were selected from the dispensary group and included into a group of CHD and DM. There were a total of 461 (64.7 %) such patients. Forty-three patients were identified in this group, who were matched for baseline systolic and diastolic blood pressures, age, gender, and DM duration and were found to have significant hypercholesterolemia. Simvastatin forte 40 mg was
prescribed to these patients at their outpatient visit. During a year, the patient made 6 visits to his/her physician (5 visits at 6-werk intervals and the sixth visit by the end of the follow-up year). The dose of simvastatin was unchanged throughout the study.

Results.In the entire dispensary group, 64.7 % of the patients had a concurrence of CHD and DM. This group of patients was at high risk for dyslipidemia. In this group, 2.8 % had a total cholesterol (TC) level of ≤ 3.5 mmol/l; 4.7 % had a low-density lipoprotein cholesterol (LDL-C) level of < 1.8 mmol/l. The total lipid profile was analyzed in only 6.3% of the patients from the entire dispensary group. 28.6 % of the patients with type 1 DM and 21.3% of those with CHD and type 2 DM took statins. Fifty-two week therapy with simvastatin forte 40 mg showed its high efficiency in real practice in decreasing the levels of atherogenic lipids and lipoproteins: TC by 27.6 % (p < 0.001), LDL-C by 36.9 % (p < 0.001), and triglycerides by 34.3 % (p < 0.001) with antiatherogenic high-density lipoprotein cholesterol elevation by 15.2 % (p < 0,001). Simvastatin forte therapy was well tolerated: the mean values of liver enzymes and the activity of creatine phosphokinase remained within the normal range. After one-year simvastatin forte therapy, the blood concentration of glucose decreased by 10.5%.

Conclusion. Simvastatin forte (40 mg/day) demonstrated good hypolipidemic efficacy, tolerability, and high safety profile in patients with CHD and DM.

1. Российские рекомендации «Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза». Кардиоваскул тер и профил 2004;(2 приложение):1–36.

2. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937–52.

3. Kannel W.B. Lipid, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110(5):1100–7.

4. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434–44.

5. Gu K., Cowie C.C., Harris M.I. Mortality in adults with and without diabetes in a national cohort of the US. Population, 1971–1993. Diabetes Care 1998;21(7):1138–45.

6. van Boven A.J., Brugemann J., de Graeff P.A. et al. The 4S study. Implications for prescribing. Drugs 1996;51(4):507–14.

7. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348(9038):1339–42.

8. Haffner S.M. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: imprelications for the prevention of coronary heart disease. Diabetes Care 1997;20(4):469–71.

9. LaRosa J.S., He J., Vupputuri S. Effect of statins on risk of coronary disease: a metaanalisis

10. of randomized controlled trials. JAMA 1999;282(24):2340–6.

11. Farmer J.A., Cotto A.M. Jr. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003;92(1A):3i–9i.

12. Kaplan N.M. The ASCOT trial: a closer look. J Hypertens 2006;24(2):211–4.

13. Кухарчук В.В., Бубнова М.Г., Кательницкая Л.И. и др. Эффективность и безопасность симвастатина у пациентов с гиперхолестеринемией (результаты многоцентрового клинического исследования). Кардиология 2003;43(5):42–7.

14. Агеев Ф.Т., Нуралиев Э.Ю., Чернина Г.В. и др. Контролируемое применение симвастатина и «обычная» терапия гиперлипидемии у больных с ИБС в амбулаторных условиях: сравнительное

15. исследование двух стратегий. (СИГНАЛ-КОНТРОЛЬ). Кардиология 2006;46(6):10–5.

16. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12–54.

17. Сусеков А.В., Зубарева М.Ю., Деев А.Д. и др. Основные результаты Московского исследования по статинам (Moscow Statin Survey. MSS). Сердце 2006;5(6):324–8.

18. Фомин И.В., Поляков Д.С. β-адреноблокаторы вчера, сегодня и завтра: смогут ли они остаться в группе основных лекарственных средств? Системн гипертенз 2011;8(2):36–42.

19. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Современный образ пациента с ХСН в Европейской части Российской Федерации (госпитальный этап). Сердечн недостат 2011;(5):255–9.

20. Развитие принципов лечения сосудистых осложнений для снижения риска при диабете второго типа. Доклад на международном симпозиуме. Барселона, Испания, январь 2006 г. Обзоры клин кардиол 2008;(13):26–40.

21. Fisher M. Diabetes and atherogenesis. Heart 2004;90(3):336–40.

22. Colboun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvaststin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placedo-controlled trial. Lancet 2004;364(9435):685–96.

23. Дедов И.И., Александров А.А. Сахарный диабет, атеросклероз и ишемическая болезнь сердца. В кн.: Руководство по атеросклерозу и ишемической болезни сердца. Под ред. Е.И. Чазова, В.В. Кухарчука, С.А. Бойцова. М.: Медиа Медика, 2007. C. 98–127.

24. Sampietro T., Bigazzi F., Dal Pino B. et al. HDL: the “new” target of cardiovascular medicine. Int J Cardiol 2006;108(2):143–54.

25. Miller N.E., Thelle D.S., Forde O.H. et al. The Tromso heart-study: high-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977;1(8019):965–8.

26. Shah P.K., Amin J. Low high density lipoprotein level associated with increased restenosis rate after coronary angioplasty. Circulation1992;85(4):1279–85.

27. Wilson R.W., Abbott R.D., Castelli W.P. High density lipoprotein cholesterol and mortality: the Framingham Heart Study. Arteriosclerosis 1988;8(6):737–41.

28. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Tromb Vasc Biol 1997;17(1):107–13.

29. Forrester J.S., Makkar R., Shah P.K. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005;111(14):1847–54.

30. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet

31. ;344(8923):633–8.

32. Strazzullo P., Kerry S.M., Barbato A. et al. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007;49(4):792–8.

33. Сусеков А.В., Рожкова Т.А., Трипотень М.И. Рандомизированное исследование ФАРВАТЕР: Часть II. Эффект аторвастатина на функцию эндотелия, растяжимость и жесткость сосудистой стенки. Кардиоваскул тер и профил 2007;6(3):68–75.

34. Zanchetti A., Crepaldi G., Bond M.G. et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double-blind trial.

35. Stroke 2004;35(12):2807–12.

36. Pyorala K., Pedersen T.R., Kjekshus J. et al. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614–20.

37. Haffner S.M., Alexander C.M., Cook T.J. et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Int Med 1999;159(22):2661–7.